 |
54 Diseases |  |
8 Trials |
|
8 Trials |  |
2662 News |  |
| «12...12131415161718192021222324» |
- ||| ledipasvir/sofosbuvir / Generic mfg.
New P3 trial, HEOR: Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection (clinicaltrials.gov) - Nov 6, 2015
P3, N=30, Not yet recruiting, Sponsor: University Health Network, Toronto
- | ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease (clinicaltrials.gov) - Nov 6, 2015
P2, N=25, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting
- ||| ledipasvir/sofosbuvir / Generic mfg.
New trial: Use-Results Surveillance Study of Harvoni (clinicaltrials.gov) - Oct 29, 2015
P=N/A, N=3000, Not yet recruiting, Sponsor: Gilead Sciences
- ledipasvir/sofosbuvir / Generic mfg.
New trial: Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir (clinicaltrials.gov) - Oct 27, 2015
P=N/A, N=15, Not yet recruiting, Sponsor: University of Colorado, Denver
- ||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial initiation date: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection (clinicaltrials.gov) - Oct 22, 2015
P3, N=200, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Initiation date: Jun 2015 --> Sep 2015
- || daclatasvir/sofosbuvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P3 trial: Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients (clinicaltrials.gov) - Oct 22, 2015
P3, N=60, Recruiting, Sponsor: Humanity & Healthy GI and Liver Centre
- | Pegasys (pegylated interferon ? -2a) / Roche, Sunvepra (asunaprevir) / BMS, Olysio (simeprevir) / J&J, Medivir
New P2 trial: SWITCH-1: Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (clinicaltrials.gov) - Oct 22, 2015
P2, N=160, Recruiting, Sponsor: Humanity & Healthy GI and Liver Centre
- ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment open, Trial primary completion date: SWIFT-C: Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection (clinicaltrials.gov) - Oct 6, 2015
P1, N=50, Recruiting, Sponsor: AIDS Clinical Trials Group
Initiation date: Jun 2015 --> Sep 2015 Active, not recruiting --> Recruiting | Trial primary completion date: Mar 2016 --> Nov 2016
- || ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection (clinicaltrials.gov) - Oct 5, 2015
P2, N=200, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Recruiting | Trial primary completion date: Mar 2016 --> Nov 2016 Trial primary completion date: Jun 2018 --> Jun 2017
- || Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
Enrollment change: A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection (clinicaltrials.gov) - Oct 2, 2015
P=N/A, N=2000, Enrolling by invitation, Sponsor: Gilead Sciences
Trial primary completion date: Jun 2018 --> Jun 2017 N=1300 --> 2000
- ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting (clinicaltrials.gov) - Sep 24, 2015
P2, N=25, Recruiting, Sponsor: Gilead Sciences
N=1300 --> 2000 Trial primary completion date: Sep 2016 --> May 2016
- | ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection (clinicaltrials.gov) - Sep 24, 2015
P2, N=26, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Sep 2016 --> May 2016 Recruiting --> Active, not recruiting
- Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) / AbbVie, Enanta Pharma, Exviera (dasabuvir) / AbbVie
New P2/3 trial: DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) (clinicaltrials.gov) - Sep 22, 2015
P2/3, N=32, Recruiting, Sponsor: Humanity & Healthy GI and Liver Centre
- ||| voxilaprevir (GS-9857) / Gilead
Enrollment closed: LEPTON: Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (clinicaltrials.gov) - Sep 14, 2015
P2, N=295, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial completion, Metastases: Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant (clinicaltrials.gov) - Sep 10, 2015
P2, N=334, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ledipasvir/sofosbuvir / Generic mfg.
New P4 trial: STOP-CO: Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant (clinicaltrials.gov) - Aug 27, 2015
P4, N=50, Not yet recruiting, Sponsor: University of California, San Francisco
- |||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders (clinicaltrials.gov) - Aug 26, 2015
P2, N=122, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Ledipasvir/Sofosbuvir Fixed-Dose Combination (clinicaltrials.gov) - Aug 13, 2015
P2, N=100, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- ||| ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed, Enrollment change: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection (clinicaltrials.gov) - Aug 11, 2015
P2, N=114, Active, not recruiting, Sponsor: Gilead Sciences
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting | N=150 --> 114
- Sunvepra (asunaprevir) / BMS, Olysio (simeprevir) / J&J, Medivir, Daklinza (daclatasvir) / BMS
Phase classification, Enrollment change: Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects (clinicaltrials.gov) - Aug 10, 2015
P2, N=18, Recruiting, Sponsor: Humanity & Healthy GI and Liver Centre
Recruiting --> Active, not recruiting | N=150 --> 114 Phase classification: P4 --> P2 | N=60 --> 18
- ||| Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Sovaldi (sofosbuvir) / Gilead
New trial: A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials (clinicaltrials.gov) - Jul 29, 2015
P=N/A, N=500, Not yet recruiting, Sponsor: Gilead Sciences
- ledipasvir/sofosbuvir / Generic mfg.
New trial: Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD) (clinicaltrials.gov) - Jul 21, 2015
P=N/A, N=24, Recruiting, Sponsor: Massachusetts General Hospital
- ||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection (clinicaltrials.gov) - Jul 21, 2015
P2, N=110, Active, not recruiting, Sponsor: Gilead Sciences
Phase classification: P4 --> P2 | N=60 --> 18 Recruiting --> Active, not recruiting
- voxilaprevir (GS-9857) / Gilead
Trial primary completion date: LEPTON: Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (clinicaltrials.gov) - Jul 16, 2015
P2, N=295, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2015 --> Apr 2016
- ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection (clinicaltrials.gov) - Jul 13, 2015
P2, N=25, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Oct 2015 --> Apr 2016 Not yet recruiting --> Recruiting
- Sunvepra (asunaprevir) / BMS, Olysio (simeprevir) / J&J, Medivir, Daklinza (daclatasvir) / BMS
Enrollment change: Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects (clinicaltrials.gov) - Jul 12, 2015
P4, N=60, Recruiting, Sponsor: Humanity & Healthy GI and Liver Centre
Not yet recruiting --> Recruiting N=40 --> 60
- || ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia (clinicaltrials.gov) - Jul 1, 2015
P4, N=1000, Enrolling by invitation, Sponsor: National Institutes of Health Clinical Center (CC)
N=40 --> 60 Trial primary completion date: Sep 2015 --> Jun 2016
- ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease (clinicaltrials.gov) - Jul 1, 2015
P2, N=25, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Sep 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- |||||||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P3 trial: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection (clinicaltrials.gov) - Jul 1, 2015
P3, N=200, Recruiting, Sponsor: Gilead Sciences
- Olysio (simeprevir) / J&J, Medivir
Enrollment open: A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection (clinicaltrials.gov) - Jun 26, 2015
P2, N=40, Recruiting, Sponsor: Janssen Sciences Ireland UC
Trial primary completion date: Dec 2015 --> Jun 2016 Not yet recruiting --> Recruiting
- | Daklinza (daclatasvir) / BMS
New P4 trial: Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients (clinicaltrials.gov) - Jun 25, 2015
P4, N=120, Recruiting, Sponsor: Humanity & Healthy GI and Liver Centre
- ||||| ledipasvir/sofosbuvir / Generic mfg.
New P4 trial: Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6 (clinicaltrials.gov) - Jun 24, 2015
P4, N=60, Recruiting, Sponsor: Stanford University
- ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection (clinicaltrials.gov) - Jun 24, 2015
P2, N=20, Active, not recruiting, Sponsor: Peter J. Ruane, M.D., Inc.
- |||||||||| ledipasvir/sofosbuvir / Generic mfg.
New P3 trial: Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection (clinicaltrials.gov) - Jun 16, 2015
P3, N=155, Recruiting, Sponsor: Gilead Sciences
- Sunvepra (asunaprevir) / BMS, Olysio (simeprevir) / J&J, Medivir, Daklinza (daclatasvir) / BMS
New P4 trial: Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects (clinicaltrials.gov) - Jun 12, 2015
P4, N=40, Recruiting, Sponsor: Humanity & Healthy GI and Liver Centre
- ribavirin / Generic mfg., daclatasvir/sofosbuvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New trial, HEOR: IFNfreeCOG: Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral Therapy (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=30, Recruiting, Sponsor: University of Wuerzburg
- | ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting (clinicaltrials.gov) - Jun 11, 2015
P2, N=25, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| radalbuvir (GS-9669) / Gilead
Trial completion: Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection (clinicaltrials.gov) - Jun 6, 2015
P2, N=362, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection (clinicaltrials.gov) - May 29, 2015
P2, N=25, Not yet recruiting, Sponsor: Gilead Sciences
- | ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed, Trial primary completion date: Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection (clinicaltrials.gov) - May 4, 2015
P2, N=40, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2015 --> Aug 2015
- Olysio (simeprevir) / J&J, Medivir
New P2 trial: A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection (clinicaltrials.gov) - Apr 20, 2015
P2, N=40, Not yet recruiting, Sponsor: Janssen Sciences Ireland UC
- ||||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection (clinicaltrials.gov) - Apr 10, 2015
P2, N=100, Recruiting, Sponsor: Gilead Sciences
- |||| ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Trial completion, Metastases: Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant (clinicaltrials.gov) - Apr 3, 2015
P2, N=339, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2015 --> Aug 2015 Active, not recruiting --> Completed
- ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: SWIFT-C: Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection (clinicaltrials.gov) - Mar 18, 2015
P1, N=44, Active, not recruiting, Sponsor: AIDS Clinical Trials Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease (clinicaltrials.gov) - Mar 17, 2015
P2, N=25, Recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting (clinicaltrials.gov) - Mar 7, 2015
P2, N=25, Not yet recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2015 --> Jul 2016
- |||| ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection (clinicaltrials.gov) - Mar 7, 2015
P2, N=85, Completed, Sponsor: Gilead Sciences
Trial primary completion date: Nov 2015 --> Jul 2016 Active, not recruiting --> Completed
- | vedroprevir (GS 9451) / Gilead
Trial completion, Trial primary completion date: Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis (clinicaltrials.gov) - Feb 23, 2015
P2, N=47, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Feb 2015
- | ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting (clinicaltrials.gov) - Jan 29, 2015
P2, N=25, Not yet recruiting, Sponsor: Gilead Sciences
- | ledipasvir/sofosbuvir / Generic mfg.
New P4 trial, IO biomarker: Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs (clinicaltrials.gov) - Jan 28, 2015
P4, N=24, Recruiting, Sponsor: Rockefeller University